What is the optimal first-line regimen for advanced non-small cell lung cancer patients with epidermal growth factor receptor mutation: a systematic review and network meta-analysis

Abstract Objectives There are currently various tyrosine kinase inhibitor (TKI)-based regimens available, and it can be challenging for clinicians to determine the most effective and safe option due to the lack of direct comparisons between these regimens. In this study, we conducted a network meta-...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Wengang Zhang, Xinyu Zhang, Wencheng Zhao, Zhiyi Guo, Xinyue Liu, Li Ye, Zhimin Chen, Kandi Xu, Yujin Liu, Hao Wang, Lishu Zhao, Qianqian Zhang, Yujie Li, Xuyang Chen, Yayi He
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2024-12-01
Serija:	BMC Pulmonary Medicine
Teme:	Epidermal growth factor receptor Tyrosine kinase inhibitors Osimertinib Network meta-analysis Non-small cell lung cancer
Online dostop:	https://doi.org/10.1186/s12890-024-03438-3
Oznake:	Označite Brez oznak, prvi označite!